M. Audran, Intérêt, limites et conséquences de la recension des facteurs de risque d'ostéoporose, Revue du Rhumatisme, vol.71, issue.9, pp.734-736, 2004.

, 9.1. Le coût associé à un faible besoin de soins est significatif pour les personnes âgées à faible revenu

, Graphique 1.8. Comparaison des résultats sur le marché du travail après la crise financière mondiale et après les récessions économiques majeures précédentes, par groupe de population

A. Malherbe, Faune ornithologique de la Sicile : avec des observations sur l'habitat ou l'apparition des oiseaux de cette ile, soit dans le reste de l'Europe, soit dans le nord de l'Afrique ; précédée d'un aperçu de l'histoire politique, scientifiqu, 1843.

, Manuel du logiciel. Aide au diagnostic en hématologie (ADH), Autoformation et aide au diagnostic en hématologie avec le logiciel ADH, vol.9, pp.227-228

, Résultats de la modélisation des retraites : Brésil en 2049 (2044) avec un âge de départ à la retraite à 55 ans pour les hommes (et 50 ans pour les femmes) : Brésil, pp.49-53, 2016.

, Graphique 12.22. Réduction du taux de létalité des IAM entre 2001 et 2011 (sur la base des admissions, dans les 30 jours suivant une admission pour IAM dans le même hôpital, pour les patients âgés d?au moins 45 ans), Les patients étaient allogreffés en majorité pour une LAM (30,7%). Les autres indications d'allogreffe de CSH étaient : hémopathies lymphoprolifératives pour 24,8% (incluant les lymphomes malins non hodgkiniens, vol.17

, La corrélation entre le pourcentage de travailleurs nés à l'étranger et le taux d'emploi de la population née dans le pays diffère sensiblement entre les pays, 2018.

, Graphique 4.1_Pourcentage de l?aide principalement et majoritairement ciblée sur l?égalité des sexes, par secteur_FRm, CSP, vol.86

H. Gardeney and D. Desmier, Suivi à long terme des leucémies aiguës myéloblastiques à risque intermédiaire et élevé après allogreffe, comparant un conditionnement myéloablatif à un conditionnement d?intensité réduite, Hématologie, vol.24, issue.3, pp.207-208, 2018.

. Devenir, . Survie, and . Patients,

, 3.12. Moyenne des taux de remplacement nets sur 60 mois, vol.27, p.7

, Financement des PME et des entrepreneurs : Tableau de bord de la France, 2007-10, Le devenir des patients est représenté Figure 15 et la description des causes de décès Tableau 9, 2013.

, Indicateur A5 : Quels sont les facteurs qui ont une influence sur la performance des élèves issus de l?immigration ?

, Pourcentage d'enfants d'immigrés originaires de pays à faible revenu qui sont nés dans leur pays d'accueil et en ont la nationalité, 2013.

, Évolution du sentiment d?efficacité personnelle des enseignants et de leur classement des capsules, Trente-huit patients, vol.27, 2020.

N. Droz, L. Gilardin, P. Cacoub, B. Godeau, A. Piette et al., Présentation et prise en charge des réactivations virales B chez les patients atteints de maladies auto-immunes et de rhumatismes inflammatoires, La Revue de Médecine Interne, vol.33, pp.A67-A68, 2012.

, Graphique 8.4. Dans les pays de l?OCDE où les écarts sont les plus grands, la satisfaction à l?égard de la vie est en moyenne 2.5 fois plus élevée dans le quintile supérieur de la distribution que dans le quintile inférieur

M. Hébert, Analyse des interactions dans le travail de co-interprétation au collège : une perspective didactique, Interactions dans le groupe et apprentissages, vol.3, pp.63-81

J. H. Falkenburg and E. H. Warren, Graft versus Leukemia Reactivity after Allogeneic Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.17, issue.1, pp.S33-S38, 2011.

J. L. Ferrara, J. E. Levine, P. Reddy, and E. Holler, Graft-versus-host disease, The Lancet, vol.373, issue.9674, pp.1550-1561, 2009.

T. A. Gooley, J. W. Chien, S. A. Pergam, S. Hingorani, M. L. Sorror et al., Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation, New England Journal of Medicine, vol.363, issue.22, pp.2091-2101, 2010.

W. D. Shlomchik, Graft-versus-host disease, Nature Reviews Immunology, vol.7, issue.5, pp.340-352, 2007.

A. Gratwohl, R. Brand, and J. Apperley, Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia, Blood, vol.100, issue.12, pp.3877-3886, 2002.

M. Griffioen, C. A. Van-bergen, and J. H. Falkenburg, Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets, Frontiers in Immunology, vol.7, p.100, 2016.

M. Slade, B. Fakhri, B. N. Savani, and R. Romee, Halfway there: the past, present and future of haploidentical transplantation, Bone Marrow Transplantation, vol.52, issue.1, pp.1-6, 2016.

C. Anasetti, B. R. Logan, and S. J. Lee, Peripheral-blood stem cells versus bone marrow from unrelated donors, N Engl J Med, vol.367, issue.16, pp.1487-96, 2012.

S. Couban, D. R. Simpson, and M. J. Barnett, A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies, Blood, vol.100, issue.5, pp.1525-1531, 2002.

N. Schmitz, M. Beksac, and D. Hasenclever, Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia, Blood, vol.100, issue.3, pp.761-767, 2002.

E. Carreras, C. Dufour, M. Mohty, N. Kröger, . The et al., Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, 12. Mohty B, Mohty M, vol.1, pp.3214-3223, 2005.

S. Lee, B. Cho, J. Kim, J. Yoon, S. Shin et al., Risk and prognostic factors for acute GVHD based on NIH consensus criteria, Bone Marrow Transplantation, vol.48, issue.4, pp.587-592, 2012.

B. R. Blazar, W. J. Murphy, and M. Abedi, Advances in graft-versus-host disease biology and therapy, Nature Reviews Immunology, vol.12, issue.6, pp.443-458, 2012.

R. Zeiser and B. R. Blazar, Acute Graft-versus-Host Disease ? Biologic Process, Prevention, and Therapy, New England Journal of Medicine, vol.377, issue.22, pp.2167-2179, 2017.

R. Zeiser and B. R. Blazar, Acute Graft-versus-Host Disease ? Biologic Process, Prevention, and Therapy, New England Journal of Medicine, vol.377, issue.22, pp.2167-2179, 2017.

H. Glucksberg, R. Storb, A. Fefer, C. D. Buckner, P. E. Neiman et al., CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,S, Transplantation, vol.18, issue.4, pp.295-304, 1974.

J. Finke, C. Schmoor, W. A. Bethge, H. Ottinger, M. Stelljes et al., Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial, The Lancet Haematology, vol.4, issue.6, pp.e293-e301, 2017.

C. G. Kanakry, E. J. Fuchs, and L. Luznik, Modern approaches to HLA-haploidentical blood or marrow transplantation, Nature Reviews Clinical Oncology, vol.13, issue.1, pp.10-24, 2015.

P. J. Martin, J. D. Rizzo, J. R. Wingard, K. Ballen, P. T. Curtin et al., First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, vol.18, issue.8, pp.1150-1163, 2012.

J. E. Levine, S. Paczesny, and S. Sarantopoulos, Clinical Applications for Biomarkers of Acute and Chronic Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.18, issue.1, pp.S116-S124, 2012.

E. Maffini, L. Giaccone, M. Festuccia, L. Brunello, I. Buondonno et al., Ruxolitinib in steroid refractory graft-vs.-host disease: a case report, Journal of Hematology & Oncology, vol.9, issue.1, p.67, 2016.

R. Zeiser and B. R. Blazar, Zeiser R, Blazar BR. Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood. 2016;127(25):3117-3126., Blood, vol.128, issue.10, pp.1441-1441, 2016.

D. Wolff, F. Ayuk, A. Elmaagacli, H. Bertz, A. Lawitschka et al., Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers, Biology of Blood and Marrow Transplantation, vol.19, issue.5, pp.767-776, 2013.

M. Grube, E. Holler, D. Weber, B. Holler, W. Herr et al., Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation?Results from a Single-Center Observational Study, Biology of Blood and Marrow Transplantation, vol.22, issue.10, pp.1781-1791, 2016.

M. Grube, E. Holler, D. Weber, B. Holler, W. Herr et al., Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation?Results from a Single-Center Observational Study, Biology of Blood and Marrow Transplantation, vol.22, issue.10, pp.1781-1791, 2016.

R. Zeiser and B. R. Blazar, Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets, New England Journal of Medicine, vol.377, issue.26, pp.2565-2579, 2017.

M. H. Jagasia, H. T. Greinix, and M. Arora, National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report, Biol Blood Marrow Transplant, vol.21, issue.3, pp.389-401, 2015.

L. Magro, E. Forcade, C. Giraud, A. Granata, N. Parquet et al., Prise en charge de la maladie du greffon contre l?hôte chronique : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bulletin du Cancer, vol.104, issue.12, pp.S145-S168, 2017.

Y. Inamoto, M. E. Flowers, B. M. Sandmaier, S. Z. Aki, P. A. Carpenter et al., Failure-free survival after initial systemic treatment of chronic graft-versus-host disease, Blood, vol.124, issue.8, pp.1363-1371, 2014.

M. E. Flowers and P. J. Martin, How we treat chronic graft-versus-host disease, Blood, vol.125, issue.4, pp.606-615, 2015.

D. Wolff, M. Schleuning, S. Von-harsdorf, U. Bacher, A. Gerbitz et al., Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.17, issue.1, pp.1-17, 2011.

S. Bhatia, L. Francisco, and A. Carter, Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study, Blood, vol.110, issue.10, pp.3784-92, 2007.

M. Weisser, C. Theilacker, S. Tschudin-sutter, R. Babikir, H. Bertz et al., Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS), Clinical Microbiology and Infection, vol.23, issue.11, pp.854-859, 2017.

M. Tomblyn, T. Chiller, H. Einsele, R. Gress, K. Sepkowitz et al., Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective, Biology of Blood and Marrow Transplantation, vol.15, issue.10, pp.1143-1238, 2009.

M. Boeckh and P. Ljungman, How we treat cytomegalovirus in hematopoietic cell transplant recipients, Blood, vol.113, issue.23, pp.5711-5719, 2009.

R. B. Freeman, The 'Indirect' Effects of Cytomegalovirus Infection, American Journal of Transplantation, vol.9, issue.11, pp.2453-2461, 2009.

T. Mori and J. Kato, Cytomegalovirus infection/disease after hematopoietic stem cell transplantation, International Journal of Hematology, vol.91, issue.4, pp.588-595, 2010.

E. Brissot, T. Alsuliman, B. Gruson, E. Hermet, Y. Tirefort et al., Conduite à tenir devant une réactivation EBV et un syndrome lymphoprolifératif à EBV, une réactivation ou infection à CMV et à HHV-6 après allogreffe de cellules souches hématopoïétiques : recommandations de la SFGM-TC (mises à jour), Bulletin du Cancer, vol.104, issue.12, pp.S181-S187, 2017.

, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

. Pic_ins_avis3_ct16715 and . Pdf,

F. M. Marty, P. Ljungman, and R. F. Chemaly, Letermovir Prophylaxis for Cytomegalovirus in

A. Thrasher and D. Goldblatt, Hematopoietic-Cell Transplantation for Chronic Granulomatous Disease, New England Journal of Medicine, vol.345, issue.5, pp.377-378, 2001.

S. V. Hecke, B. Calcoen, K. Lagrou, and J. Maertens, Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients, Future Microbiology, vol.14, issue.3, pp.175-184, 2019.

H. E. Heslop, How I treat EBV lymphoproliferation, Blood, vol.114, issue.19, pp.4002-4008, 2009.

T. Teshima, JAK inhibitors: a home run for GVHD patients?, Blood, vol.123, issue.24, pp.3691-3693, 2014.

, Évaluation des systèmes implantables de neurostimulation médullaire par la Haute Autorité de santé (HAS) en France, Chirurgie de la douleur, pp.143-148, 2014.

C. Harrison, J. Kiladjian, H. K. Al-ali, H. Gisslinger, R. Waltzman et al., JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, New England Journal of Medicine, vol.366, issue.9, pp.787-798, 2012.

S. Verstovsek, R. A. Mesa, J. Gotlib, R. S. Levy, V. Gupta et al., A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, New England Journal of Medicine, vol.366, issue.9, pp.799-807, 2012.

S. Verstovsek, J. Gotlib, R. A. Mesa, A. M. Vannucchi, J. Kiladjian et al., Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses, Journal of Hematology & Oncology, vol.10, issue.1, p.156, 2017.

A. M. Vannucchi, J. J. Kiladjian, M. Griesshammer, T. Masszi, S. Durrant et al., Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera, New England Journal of Medicine, vol.372, issue.5, pp.426-435, 2015.

. Vidal, Graphique 4.7. Étapes du cycle de l?action publique auxquelles le centre de gouvernement consulte les parties prenantes, 2016

J. Vidal,

S. Verstovsek, R. A. Mesa, J. Gotlib, R. S. Levy, V. Gupta et al., Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I, Haematologica, vol.100, issue.4, pp.479-488, 2015.

E. Ascari, The history of Haematologica, Haematologica, vol.100, issue.1, pp.1-3, 2014.

S. Ajayi, H. Becker, H. Reinhardt, M. Engelhardt, R. Zeiser et al., Ruxolitinib, Small Molecules in Hematology, vol.212, pp.119-132, 2018.

F. Lussana, M. Cattaneo, A. Rambaldi, and A. Squizzato, Ruxolitinib-associated infections: A systematic review and meta-analysis, American Journal of Hematology, vol.93, issue.3, pp.339-347, 2017.

S. Lescuyer, M. Ledoux, S. Gravier, S. Natarajan-amé, C. Duval et al., Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera, International Journal of Infectious Diseases, vol.80, pp.134-136, 2019.

P. Sylvine, S. Thomas, and E. Pirayeh, Infections associated with ruxolitinib: study in the French Pharmacovigilance database, Annals of Hematology, vol.97, issue.5, pp.913-914, 2018.

N. Polverelli, M. Breccia, G. Benevolo, B. Martino, A. Tieghi et al., Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients, American Journal of Hematology, vol.92, issue.1, pp.37-41, 2016.

N. Polverelli, G. A. Palumbo, G. Binotto, E. Abruzzese, G. Benevolo et al., Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients, Hematological Oncology, vol.36, issue.3, pp.561-569, 2018.

S. Spoerl, N. R. Mathew, M. Bscheider, A. Schmitt-graeff, S. Chen et al., Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease, Blood, vol.123, issue.24, pp.3832-3842, 2014.

R. Zeiser, A. Burchert, and C. Lengerke, Ruxolitinib in corticosteroid-refractory graftversus-host disease after allogeneic stem cell transplantation: a multi-center survey, Leukemia, vol.29, issue.10, pp.2062-2070, 2015.

B. Modi, M. Hernandez-henderson, D. Yang, J. Klein, S. Dadwal et al., Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease, Biology of Blood and Marrow Transplantation, vol.25, issue.2, pp.265-269, 2019.

P. Khandelwal, A. Teusink-cross, S. M. Davies, A. S. Nelson, C. E. Dandoy et al., Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients, Biology of Blood and Marrow Transplantation, vol.23, issue.7, pp.1122-1127, 2017.

. Steroid-refractory, Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients, Biol Blood Marrow Transplant, vol.23, issue.7, pp.1122-1129, 2017.

S. Abedin, E. Mckenna, S. Chhabra, M. Pasquini, N. N. Shah et al., Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.25, issue.8, pp.1689-1694, 2019.

S. Abedin, E. Mckenna, S. Chhabra, M. Pasquini, N. N. Shah et al., Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.25, issue.8, pp.1689-1694, 2019.

D. Assouan, D. Lebon, A. Charbonnier, B. Royer, J. Marolleau et al., Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus -host disease, British Journal of Haematology, vol.181, issue.5, pp.687-689, 2017.

H. J. Khoury, A. A. Langston, V. K. Kota, J. A. Wilkinson, I. Pusic et al., Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease, Bone Marrow Transplantation, vol.53, issue.7, pp.826-831, 2018.

N. Von-bubnoff, G. Ihorst, O. Grishina, N. Röthling, H. Bertz et al., Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628), BMC Cancer, vol.18, issue.1, p.1132, 2018.

M. Jagasia, R. Zeiser, M. Arbushites, P. Delaite, B. Gadbaw et al., Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials, Immunotherapy, vol.10, issue.5, pp.391-402, 2018.

M. Jagasia, M. Perales, M. A. Schroeder, H. Ali, N. N. Shah et al., Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease, Blood, vol.132, issue.Supplement 1, pp.601-601, 2018.

M. Jagasia, M. Perales, M. A. Schroeder, H. Ali, N. N. Shah et al., Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease, Blood, vol.132, issue.Supplement 1, pp.601-601, 2018.

J. D. Kalbfleisch and R. L. Prentice, The Statistical Analysis of Failure Time Data, 2002.

G. Vicent, M. Molina, B. , G. De-pablo, J. Castillo et al., Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results, Am J Hematol, vol.94, issue.3, pp.319-345, 2019.

A. Heine, S. A. Held, S. N. Daecke, S. Wallner, S. P. Yajnanarayana et al., The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo, Blood, vol.122, issue.7, pp.1192-1202, 2013.

T. W. Kuijpers, P. A. Baars, C. Dantin, M. Van-den-burg, R. A. Van-lier et al., Human NK cells can control CMV infection in the absence of T cells, Blood, vol.112, issue.3, pp.914-915, 2008.

K. Schönberg, J. Rudolph, M. Vonnahme, S. Parampalli-yajnanarayana, I. Cornez et al., JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms, Cancer Research, vol.75, issue.11, pp.2187-2199, 2015.

K. Schönberg, J. Rudolph, M. Vonnahme, S. Parampalli-yajnanarayana, I. Cornez et al., JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms, Cancer Research, vol.75, issue.11, pp.2187-2199, 2015.

M. Febvre-james, V. Lecureur, Y. Augagneur, A. Mayati, and O. Fardel, Repression of interferon ?-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages, International Immunopharmacology, vol.54, pp.354-365, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01699219